Research paperCombined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate

Add time:09/04/2019    Source:sciencedirect.com

Epidermal growth factor receptor inhibitors (EGFR-TKIs) represent a class of compounds widely used in anticancer therapy. An increasing number of studies reports on combination therapies in which the block of the EGFR-TK activity is associated with inhibition of its downstream pathways, as PI3K-Akt. Sulforaphane targets the PI3K-Akt pathway whose dysregulation is implicated in many functions of cancer cells. According to these considerations, a series of multitarget molecules have been designed by combining key structural features derived from an EGFR-TKI, PD168393, and the isothiocyanate sulforaphane. Among the obtained molecules 1–6, compound 6 emerges as a promising lead compound able to exert antiproliferative and proapoptotic effects in A431 epithelial cancer cell line by covalently binding to EGFR-TK, and reducing the phosphorylation of Akt without affecting the total Akt levels.

We also recommend Trading Suppliers and Manufacturers of 2-BROMOPHENYL ISOTHIOCYANATE (cas 13037-60-0). Pls Click Website Link as below: cas 13037-60-0 suppliers

Prev:One-pot synthesis of 1,4-dihydro-3,1-benzoxazine-2-thiones by the reaction of 2-lithiophenyl isothiocyanates with aldehydes or ketones
Next:Base-promoted synthesis of 1H,3H-pyrrolo[1,2-c]thiazol-3-imine derivatives via [3+2] annulation of 2-alkynylpyrroles with isothiocyanates)